Surrozen (SRZN) Retained Earnings (2020 - 2026)
Surrozen (SRZN) posted quarterly Retained Earnings of -$654.8 million for Q1 2026, down 305.98% year-over-year from $317.9 million in Q1 2025, and down 24.18% quarter-over-quarter from -$527.3 million in Q4 2025.
Surrozen (SRZN) Retained Earnings (2020 - 2026) Analysis & Trends
Surrozen's Retained Earnings history runs 7 years deep, the most recent figure standing at -$654.8 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 305.98% year-over-year to -$654.8 million; the TTM figure through Mar 2026 stood at -$654.8 million (down 305.98% YoY), while the FY2025 annual figure was -$527.3 million, down 299.82% from the prior year.
- Retained Earnings for Q1 2026 stood at -$654.8 million, down from -$527.3 million in the prior quarter.
- The five-year high for Retained Earnings was $317.9 million in Q1 2025, with the low at -$654.8 million in Q1 2026.
- The 5-year median for Retained Earnings is -$177.9 million (2022), against an average of -$92.8 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings plunged 2670.01% in 2022, then surged 256.45% in 2023.
- Surrozen's Retained Earnings stood at $254.9 million in 2022, then tumbled by 186.98% to -$221.7 million in 2023, then jumped by 219.03% to $263.9 million in 2024, then plunged by 299.82% to -$527.3 million in 2025, then decreased by 24.18% to -$654.8 million in 2026.
- Business Quant data shows SRZN's Retained Earnings at -$654.8 million in Q1 2026, -$527.3 million in Q4 2025, and -$344.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -604.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -604.61 Mn |
| Mar 31, 2026 | -654.80 Mn |
| Dec 31, 2025 | -527.29 Mn |
| Sep 30, 2025 | -344.13 Mn |
| Jun 30, 2025 | -272.48 Mn |
| Mar 31, 2025 | 317.90 Mn |
| Dec 31, 2024 | 263.88 Mn |
| Sep 30, 2024 | 262.89 Mn |
| Jun 30, 2024 | -255.79 Mn |
| Mar 31, 2024 | -230.50 Mn |
| Dec 31, 2023 | -221.70 Mn |
| Sep 30, 2023 | 258.31 Mn |
| Jun 30, 2023 | 257.39 Mn |
| Mar 31, 2023 | -192.95 Mn |
| Dec 31, 2022 | 254.90 Mn |
| Sep 30, 2022 | -177.90 Mn |
| Jun 30, 2022 | -164.52 Mn |
| Mar 31, 2022 | -150.60 Mn |
| Dec 31, 2021 | 252.46 Mn |
| Sep 30, 2021 | -127.70 Mn |